 |
|
C-Reactive Protein and Cardiovascular Risk in the Framingham Study
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Limitations in the design and analysis of C-reactive protein (CRP) data presented by Wilson et al1 within the Framingham Heart Study need careful consideration before any conclusions regarding the clinical utility of this inflammatory biomarker are drawn.
The authors used an old assay for CRP that was previously deemed inaccurate for the evaluation of high-sensitivity CRP2 and as a consequence was abandoned by other researchers and was not validated by the Centers for Disease Control and Prevention.3 The Framingham analysis also includes the soft end points of angina pectoris, "coronary insufficiency," intermittent claudication, and reported congestive heart failure, a surprising choice given prior work by the same authors emphasizing the importance of hard end points for risk prediction. The analysis also combines sexes despite evidence of statistical interaction, a choice presumably made owing to a lack of power to address the primary issues being raised. Last, the data contradict prior . . . [Full Text of this Article]
AUTHOR INFORMATION
Paul Ridker, MD;
Nader Rifai, PhD;
Wolfgang Koenig, MD;
Roger S. Blumenthal, MD
RELATED ARTICLES
C-Reactive Protein and Cardiovascular Risk in the Framingham Study—Reply
Peter W. F. Wilson, Michael Pencina, Ralph B. D’Agostino, Sr, and Christopher J. O’Donnell
Arch Intern Med. 2006;166(12):1328.
EXTRACT
| FULL TEXT
C-Reactive Protein and Risk of Cardiovascular Disease in Men and Women From the Framingham Heart Study
Peter W. F. Wilson, Byung-Ho Nam, Michael Pencina, Ralph B. D’Agostino, Sr, Emelia J. Benjamin, and Christopher J. O’Donnell
Arch Intern Med. 2005;165(21):2473-2478.
ABSTRACT
| FULL TEXT
|
